2015 Prostate Cancer Research Highlights
- The Prostate Cancer Clinical Trials Consortium: Enabling the Practice of Precision Medicine
- Restriction Spectrum Imaging (RSI): A Rapid, Low-Cost, Non-Invasive Method for Distinguishing Indolent from Aggressive Prostate Cancer
- Dual-Targeting of AR and AKT Pathways by Berberine in Castration-Resistant Prostate Cancer
- Targeting DNA-Dependent Protein Kinase (DNAPK) to Prevent Radiotherapy Resistance in Prostate Cancer
- Identification and Targeting of Tyrosine Kinase Activity in Prostate Cancer Initiation, Progression, and Metastasis
- Leveraging RB Status to Define Therapy for Castrate-Resistant Prostate Cancer
- Biological and Genomic Differences of ERG Oncoprotein-Stratified Prostate Cancers from African and Caucasian Americans
- Global Epigenetic Changes May Underlie Ethnic Differences and Susceptibility to Prostate Cancer
- Development and Evaluation of a Blood Based Biomarker Assay to Measure Response to Prostate Cancer Therapies Enzalutamide and Abiraterone
- Low-Risk Prostate Cancer Patients Can Forgo Immediate Treatment
- Blocking T-Cell Co-Inhibitory Molecules to Improve Immune Response to Prostate Cancer